Application of Quality by Design Paradigm to the Manufacture of Protein Therapeutics

© 2012 Kontoravdi et al., licensee InTech. This is an open access chapter distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Application of Quality by Design Paradigm to the Manufacture of Protein Therapeutics

[1]  Nigel Jenkins,et al.  Getting the glycosylation right: Implications for the biotechnology industry , 1996, Nature Biotechnology.

[2]  A. Bull,et al.  Glucose‐limited chemostat culture of chinese hamster ovary cells producing recombinant human interferon‐γ , 1992, Biotechnology and bioengineering.

[3]  Shigeru Iida,et al.  Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC , 2007, BMC Biotechnology.

[4]  Jack Hoopes,et al.  Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins , 2006, Science.

[5]  Cleo Kontoravdi,et al.  Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns , 2010, Biotechnology progress.

[6]  Dirk C Hinz,et al.  Process analytical technologies in the pharmaceutical industry: the FDA’s PAT initiative , 2006, Analytical and bioanalytical chemistry.

[7]  Janice M. Reichert,et al.  Development trends for new cancer therapeutics and vaccines. , 2008, Drug discovery today.

[8]  Lai-Xi Wang,et al.  Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. , 2011, Journal of the American Chemical Society.

[9]  Andrew J. S. Jones,et al.  Analysis of polypeptides and proteins , 1993 .

[10]  M. Fukuda,et al.  Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. , 1989, Blood.

[11]  J. Egrie,et al.  Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. , 2003, Experimental hematology.

[12]  H. P. Sørensen,et al.  Advanced genetic strategies for recombinant protein expression in Escherichia coli. , 2005, Journal of biotechnology.

[13]  Uwe Kärst,et al.  Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. , 2003, Biotechnology and bioengineering.

[14]  S. Brooks,et al.  Strategies for Analysis of the Glycosylation of Proteins: Current Status and Future Perspectives , 2009, Molecular biotechnology.

[15]  L. Joshi,et al.  Glycobiomimics and glycobiosensors. , 2010, Biochemical Society transactions.

[16]  Jared J. Aumiller,et al.  A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins. , 2003, Glycobiology.

[17]  Pengyuan Yang,et al.  Identification of N-glycan of alpha-fetoprotein by lectin affinity microarray , 2008, Journal of Cancer Research and Clinical Oncology.

[18]  Florian M Wurm,et al.  Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  Y. Kao,et al.  On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format. , 2011, Analytical biochemistry.

[20]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[21]  P. P. Gray,et al.  Role of environmental conditions on the expression levels, glycoform pattern and levels of sialyltransferase for hFSH produced by recombinant CHO cells , 2004, Cytotechnology.

[22]  H. Yagi,et al.  Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. , 2006, Biochimica et biophysica acta.

[23]  J. Hollister,et al.  Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycans. , 2002, Biochemistry.

[24]  Laura A Palomares,et al.  Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum‐supplemented, serum‐free or chemically defined media , 2007, Biotechnology and applied biochemistry.

[25]  Lawrence X. Yu.  Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[26]  Andrea Schenker-Wicki,et al.  Accreditation and Quality Assurance: The Swiss Model , 2002 .

[27]  Raymond A Dwek,et al.  Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. , 2003, Glycobiology.

[28]  U. Klingmüller,et al.  The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. , 1995, Cold Spring Harbor symposia on quantitative biology.

[29]  C. Szymanski,et al.  Evidence for a system of general protein glycosylation in Campylobacter jejuni , 1999, Molecular microbiology.

[30]  M. Wadhwa,et al.  Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF. , 2003, Developments in biologicals.

[31]  F. J. Krambeck,et al.  A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. , 2009, Glycobiology.

[32]  X. Chen,et al.  Sensitive and Specific Detection of the Non-Human Sialic Acid N-Glycolylneuraminic Acid In Human Tissues and Biotherapeutic Products , 2009, PloS one.

[33]  H. Schellekens.  Immunogenicity of therapeutic proteins. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  Yoshiki Yamaguchi,et al.  Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. , 2007, Journal of molecular biology.

[35]  A. Rathore,et al.  Quality by Design: Industrial Case Studies on Defining and Implementing Design Space for Pharmaceutical Processes Part 1 , 2008 .

[36]  Basant Sharma,et al.  Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. , 2007, Biotechnology advances.

[37]  D K Robinson,et al.  Industrial choices for protein production by large-scale cell culture. , 2001, Current opinion in biotechnology.

[38]  Da Ren,et al.  Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. , 2008, Biochemistry.

[39]  A. Edge,et al.  ENZYMATIC REMOVAL OF ALPHA‐GALACTOSYL EPITOPES FROM PORCINE ENDOTHELIAL CELLS DIMINISHES THE CYTOTOXIC EFFECT OF NATURAL ANTIBODIES , 1995, Transplantation.

[40]  C. Barbas,et al.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Aebi,et al.  Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Jefferis,et al.  A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. , 1990, The Biochemical journal.

[43]  A. Shepherd,et al.  Characterisation of endogenous retrovirus in rodent cell lines used for production of biologicals. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[44]  E. Kabat,et al.  Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. , 1991, The EMBO journal.

[45]  C. Goochee,et al.  A mathematical model of sialylation of N-linked oligosaccharides in the trans-Golgi network. , 1997, Glycobiology.

[46]  A. Whitty,et al.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). , 1998, Pharmaceutical research.

[47]  J. Adamson,et al.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.

[48]  Jianwei Zhu,et al.  Mammalian cell protein expression for biopharmaceutical production. , 2012, Biotechnology advances.

[49]  H. Spiegelberg,et al.  The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. , 1968, Biochemistry.

[50]  Pauline M Rudd,et al.  Multiplexed analytical glycomics: rapid and confident IgG N-glycan structural elucidation. , 2011, Journal of proteome research.

[51]  N. Karlsson,et al.  Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins. , 2001, Glycobiology.

[52]  M. Hill,et al.  Lectin magnetic bead array for biomarker discovery. , 2010, Journal of proteome research.

[53]  Martin Gawlitzek,et al.  Effect of different cell culture conditions on the polypeptide integrity and N‐glycosylation of a recombinant model glycoprotein , 1995, Biotechnology and bioengineering.

[54]  Saurabh Aggarwal,et al.  What's fueling the biotech engine--2010 to 2011. , 2011, Nature biotechnology.

[55]  Markus Aebi,et al.  Definition of the bacterial N‐glycosylation site consensus sequence , 2006, The EMBO journal.

[56]  Eleftherios T. Papoutsakis,et al.  Culture pH Affects Expression Rates and Glycosylation of Recombinant Mouse Placental Lactogen Proteins by Chinese Hamster Ovary (CHO) Cells , 1993, Bio/Technology.

[57]  D. James,et al.  Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro , 2005, Biotechnology progress.

[58]  R. Dwek,et al.  Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG , 1985, Nature.

[59]  T. Boone,et al.  Role of glycosylation on the secretion and biological activity of erythropoietin. , 1992, Biochemistry.

[60]  Antti Hassinen,et al.  Elevated Golgi pH impairs terminal N‐glycosylation by inducing mislocalization of Golgi glycosyltransferases , 2009, Journal of cellular physiology.

[61]  C. Winearls,et al.  EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS , 1986, The Lancet.

[62]  K. Polizzi,et al.  In Situ Monitoring of Intracellular Glucose and Glutamine in CHO Cell Culture , 2012, PloS one.

[63]  J. Dennis,et al.  High‐throughput lectin magnetic bead array‐coupled tandem mass spectrometry for glycoprotein biomarker discovery , 2011, Electrophoresis.

[64]  Sumeet Sharma,et al.  Pharmaceutical Quality by Design , 2013 .

[65]  Frederick G Vogt,et al.  Development of quality-by-design analytical methods. , 2011, Journal of pharmaceutical sciences.

[66]  M. Butler,et al.  Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. , 1998, Journal of biotechnology.

[67]  Jinyou Zhang.  Mammalian Cell Culture for Biopharmaceutical Production , 2010 .

[68]  Gregory Stephanopoulos,et al.  Metabolic effects on recombinant interferon‐γ glycosylation in continuous culture of Chinese hamster ovary cells , 1999 .

[69]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[70]  Danny Chee Furng Wong,et al.  Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. , 2005, Biotechnology and bioengineering.

[71]  K. Olden,et al.  Carbohydrate moieties of glycoproteins. A re-evaluation of their function. , 1982, Biochimica et biophysica acta.

[72]  J. Briggs,et al.  Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.

[73]  D. James,et al.  Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. , 2001, Biotechnology and bioengineering.

[74]  A Helenius,et al.  How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. , 1994, Molecular biology of the cell.

[75]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[76]  R. Ishikawa,et al.  Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. , 2006, Journal of chromatography. A.

[77]  H. Tachibana,et al.  Changes of monosaccharide availability of human hybridoma lead to alteration of biological properties of human monoclonal antibody , 2004, Cytotechnology.

[78]  Y. Ikeda,et al.  N-Glycosylation engineering of lepidopteran insect cells by the introduction of the beta1,4-N-acetylglucosaminyltransferase III gene. , 2010, Glycobiology.

[79]  J E Bailey,et al.  A mathematical model of N-linked glycoform biosynthesis. , 1997, Biotechnology and bioengineering.

[80]  W. Hancock,et al.  Monitoring of Glycoprotein Products in Cell Culture Lysates Using Lectin Affinity Chromatography and Capillary HPLC Coupled to Electrospray Linear Ion Trap‐Fourier Transform Mass Spectrometry (LTQ/FTMS) , 2006, Biotechnology progress.

[81]  J. Trill,et al.  Production of monoclonal antibodies in COS and CHO cells. , 1995, Current opinion in biotechnology.

[82]  R. Senger,et al.  Effect of Shear Stress on Intrinsic CHO Culture State and Glycosylation of Recombinant Tissue‐Type Plasminogen Activator Protein , 2008, Biotechnology progress.

[83]  Wei-Shou Hu,et al.  Systems Analysis of N-Glycan Processing in Mammalian Cells , 2007, PloS one.

[84]  J. Segura,et al.  Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). , 2008, Analytical biochemistry.

[85]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[86]  J W Fisher,et al.  Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. , 1988, The Journal of biological chemistry.

[87]  M. Takeuchi,et al.  Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. , 1995, Blood.

[88]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[89]  Jae-Jin Jeon,et al.  Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant CHO cells , 2008, Biotechnology and bioengineering.

[90]  Lai-Xi Wang,et al.  A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation , 2010, Nature chemical biology.

[91]  J. Egrie,et al.  Erythropoietin: gene cloning, protein structure, and biological properties. , 1986, Cold Spring Harbor symposia on quantitative biology.

[92]  M. Butler,et al.  Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation. , 2000, Biotechnology and bioengineering.

[93]  K. Aoki,et al.  Characterization and biological effects of recombinant human erythropoietin. , 1986, Immunobiology.

[94]  A. Memarnejadian,et al.  Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. , 2010, Protein expression and purification.

[95]  R J Harris,et al.  Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. , 1995, Journal of chromatography. A.

[96]  R. Ionescu,et al.  Fragmentation of monoclonal antibodies , 2011, mAbs.

[97]  R Thorpe,et al.  Fragmentation of Therapeutic Human Immunoglobulin Preparations , 1995, Vox sanguinis.

[98]  H. Schachter.  Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. , 1986, Advances in experimental medicine and biology.

[99]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[100]  K. Aoki,et al.  S7.7 The role of carbohydrate on the biological activity of erythropoietin , 1993, Glycoconjugate Journal.

[101]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[102]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.

[103]  Gregory Stephanopoulos,et al.  Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells , 2000, IBM J. Res. Dev..

[104]  K I Kaitin,et al.  Deconstructing the Drug Development Process: The New Face of Innovation , 2010, Clinical pharmacology and therapeutics.

[105]  Teresa Mitchell,et al.  Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris. , 2012, Journal of biotechnology.

[106]  Robert M. Anthony,et al.  Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc , 2008, Science.

[107]  B. Imperiali,et al.  Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. , 1999, Current opinion in chemical biology.

[108]  R. Wagner,et al.  Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. , 1998, Biotechnology and bioengineering.

[109]  J. Reichert,et al.  World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA , 2012, mAbs.

[110]  Robert L. Glass.  The Loyal Opposition - On Design , 1999, IEEE Software.

[111]  E. Hardy,et al.  Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. , 2000, Journal of biotechnology.

[112]  R. Dwek,et al.  Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. , 1996, The Biochemical journal.

[113]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[114]  Seok-Woo Kang,et al.  Galatosylation and sialylation of mammalian glycoproteins produced by baculovirus-madiated gene expression in insect cells , 2005, Biotechnology Letters.

[115]  Bernd Hitzmann,et al.  On-line infrared spectroscopy for bioprocess monitoring , 2010, Applied Microbiology and Biotechnology.

[116]  M. Valvano,et al.  Functional Characterization and Membrane Topology of Escherichia coli WecA, a Sugar-Phosphate Transferase Initiating the Biosynthesis of Enterobacterial Common Antigen and O-Antigen Lipopolysaccharide , 2007, Journal of bacteriology.

[117]  R. Derynck,et al.  Expression of human fibroblast interferon gene in Escherichia coli , 1980, Nature.

[118]  Toru Maruyama,et al.  The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. , 2003, Biochimica et biophysica acta.

[119]  T. Gerngross,et al.  Glycosylation engineering in yeast: the advent of fully humanized yeast. , 2007, Current opinion in biotechnology.

[120]  S L Morrison,et al.  Effect of glycosylation on antibody function: implications for genetic engineering. , 1997, Trends in biotechnology.

[121]  C. Szymanski,et al.  Structure of the N-Linked Glycan Present on Multiple Glycoproteins in the Gram-negative Bacterium, Campylobacter jejuni * , 2002, The Journal of Biological Chemistry.

[122]  Naoyuki Taniguchi,et al.  Capillary electrophoresis-electrospray ionization mass spectrometry for rapid and sensitive N-glycan analysis of glycoproteins as 9-fluorenylmethyl derivatives. , 2008, Glycobiology.

[123]  E. T. Chin,et al.  The use of a porous graphitic carbon column for desalting hydrophilic peptides prior to matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 1999, Analytical biochemistry.

[124]  Renate Kunert,et al.  Analysis of immunoglobulin glycosylation by LC‐ESI‐MS of glycopeptides and oligosaccharides , 2008, Proteomics.

[125]  Stacey Ma,et al.  Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[126]  P. Lengyel,et al.  The interferon system. A bird's eye view of its biochemistry. , 1992, The Journal of biological chemistry.

[127]  Simon J North,et al.  N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. , 2002, Science.

[128]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[129]  J. Suttie.  Report of Workshop on expression of vitamin K-dependent proteins in bacterial and mammalian cells, Madison, Wisconsin, USA, April 1986. , 1986, Thrombosis research.

[130]  Adrian Whitty,et al.  Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.

[131]  Stefan N. Constantinescu,et al.  The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction , 1999, Trends in Endocrinology & Metabolism.

[132]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[133]  W. Miller,et al.  Hyperosmotic Stress and Elevated pCO2 Alter Monoclonal Antibody Charge Distribution and Monosaccharide Content , 2002, Biotechnology progress.

[134]  C. Kontoravdi,et al.  A dynamic mathematical model for monoclonal antibody N‐linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus , 2011, Biotechnology progress.

[135]  M B Sliwkowski,et al.  Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. , 2000, Biotechnology and bioengineering.

[136]  A. Dell,et al.  Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. , 1988, Biochemistry.

[137]  V. Dechavanne,et al.  Design of Experiment in CHO and HEK transient transfection condition optimization. , 2011, Protein expression and purification.

[138]  Y. Sanai,et al.  Monoclonal antibody directed to a Hanganutziu-Deicher active ganglioside, GM2 (NeuGc). , 1988, Biochimica et biophysica acta.

[139]  J. Rohrer,et al.  Five-minute glycoprotein sialic acid determination by high-performance anion exchange chromatography with pulsed amperometric detection. , 2011, Analytical Biochemistry.

[140]  Quynh-Thu Le,et al.  Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose , 2008 .

[141]  R. Lockey,et al.  Immunologic responses to therapeutic biologic agents. , 2008, Journal of investigational allergology & clinical immunology.

[142]  Terrance A Stadheim,et al.  Challenges in therapeutic glycoprotein production. , 2006, Current opinion in biotechnology.

[143]  R. Jefferis,et al.  Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. , 1987, Biochemistry.

[144]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[145]  Andrew M Goetze,et al.  Assessing monoclonal antibody product quality attribute criticality through clinical studies , 2010, mAbs.

[146]  Renate Kunert,et al.  Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo‐Fc expressing CHO cells cultivated in controlled batch bioreactors , 2006, Biotechnology and bioengineering.

[147]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[148]  B Overdijk,et al.  The effect of increasing nucleotide-sugar concentrations on the incorporation of sugars into glycoconjugates in rat hepatocytes. , 1995, The Biochemical journal.

[149]  D. Magrath,et al.  WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological susbstances no. 50). , 1998, Biologicals : journal of the International Association of Biological Standardization.

[150]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[151]  M J Keen,et al.  Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. , 1995, Glycobiology.

[152]  M. Takeuchi,et al.  Asn-linked sugar chain structures of recombinant human thrombopoietin produced in Chinese hamster ovary cells , 1999, Glycoconjugate Journal.

[153]  S L Morrison,et al.  Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. , 1999, Journal of immunology.

[154]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[155]  J. Piret,et al.  Dependence on glucose limitation of the pCO2 influences on CHO cell growth, metabolism and IgG production , 2007, Biotechnology and bioengineering.

[156]  Rick Mullin,et al.  Beyond The Patent Cliff , 2013 .

[157]  Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development , Manufacturing , and Quality Assurance , 2004 .

[158]  Stacey Ma,et al.  Capillary electrophoresis-mass spectrometry as a characterization tool for therapeutic proteins. , 2006, Analytical biochemistry.

[159]  Mark J. Bailey,et al.  A platform for high-throughput molecular characterization of recombinant monoclonal antibodies. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[160]  R. Ionescu,et al.  Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. , 2008, Current pharmaceutical biotechnology.

[161]  M. Betenbaugh,et al.  A mathematical model of N-linked glycosylation. , 2005, Biotechnology and bioengineering.

[162]  J. Lofgren,et al.  Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins , 1999, Nature Biotechnology.

[163]  Jared J. Aumiller,et al.  A new glycoengineered insect cell line with an inducibly mammalianized protein N-glycosylation pathway. , 2012, Glycobiology.

[164]  Peter D. Senter,et al.  Abstract B133: SEA technology: A novel strategy for enhancing antibody effector function , 2009 .

[165]  Kai Griebenow,et al.  Effects of glycosylation on the stability of protein pharmaceuticals. , 2009, Journal of pharmaceutical sciences.

[166]  E. Oh,et al.  On-chip detection of protein glycosylation based on energy transfer between nanoparticles. , 2009, Biosensors & bioelectronics.

[167]  Gyun Min Lee,et al.  CHO cells in biotechnology for production of recombinant proteins: current state and further potential , 2012, Applied Microbiology and Biotechnology.

[168]  Nigel Jenkins,et al.  Effect of lipid supplements on the production and glycosylation of recombinant interferon-γ expressed in CHO cells , 2004, Cytotechnology.

[169]  H. Lodish,et al.  Expression cloning of the murine erythropoietin receptor , 1989, Cell.

[170]  Lihua Huang,et al.  Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. , 2006, Analytical biochemistry.

[171]  B. Welch.  The structure , 1992 .

[172]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[173]  A Jungbauer,et al.  Analysis of aggregates of human immunoglobulin G using size-exclusion chromatography, static and dynamic light scattering. , 2003, Journal of chromatography. A.

[174]  Saurabh Aggarwal,et al.  What's fueling the biotech engine? , 2007, Nature Biotechnology.

[175]  Alex Eon-Duval,et al.  Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach , 2012, Biotechnology progress.

[176]  M. Aebi,et al.  An engineered eukaryotic protein glycosylation pathway in Escherichia coli. , 2012, Nature chemical biology.

[177]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[178]  A. Markham,et al.  A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications , 2012 .

[179]  N. Hashii,et al.  The significance of glycosylation analysis in development of biopharmaceuticals. , 2009, Biological & pharmaceutical bulletin.

[180]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[181]  D. Jarvis,et al.  Substrate Specificities and Intracellular Distributions of Three N-glycan Processing Enzymes Functioning at a Key Branch Point in the Insect N-Glycosylation Pathway* , 2012, The Journal of Biological Chemistry.

[182]  A J Sinskey,et al.  A modeling framework for the study of protein glycosylation , 1996, Biotechnology and bioengineering.

[183]  M. Cazzola,et al.  Use of recombinant human erythropoietin outside the setting of uremia. , 1997, Blood.

[184]  Ron S. Kenett,et al.  Quality by Design applications in biosimilar pharmaceutical products , 2008 .

[185]  Ron Taticek,et al.  A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. , 2008, Analytical biochemistry.

[186]  Janice M. Reichert,et al.  A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.